Enolase peptide conjugate vaccines against
The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologs encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus . The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.
1. An isolated enolase peptide derivative, wherein said derivative comprises an enolase peptide and one or more additional not naturally associated regions or moieties covalently joined to said amino acid sequence, wherein the enolase peptide consists of a sequence of amino acids as set forth in SEQ ID NO:6 or consists essentially of SEQ ID NO:6 and between 1 and 10 additional amino acids, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
2. An immunogenic composition able to induce a protective immune response in a patient against S. aureus infection comprising an immunologically effective amount of an isolated enolase peptide, and a pharmaceutically acceptable carrier, and an amount of adjuvant that enhances the immune response, wherein the enolase peptide consists of SEQ ID NO:6 or is a derivative of SEQ ID NO:6 consisting essentially of SEQ ID NO:6 and between 1 and 10 additional amino acids.
3. The immunogenic composition of claim 2 , wherein the enolase peptide is a derivative of SEQ ID NO:6 consisting of the amino acid sequence as set forth in SEQ ID NO: 6 with an additional N-terminal methionine.